Table: Kyowa Kirin -9-MTH group results (IFRS)
Oct 31 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2024 Sep 30, 2023 Dec 31, 2024
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 362.80 306.05 492.00
(+18.5 pct) (+7.9 pct) (+11.3 pct)
(-4.9 pct)
Operating
Pretax 71.57 64.34 92.00
(+11.2 pct) (+6.5 pct) (-5.3 pct)
Net 55.90 53.55 68.00
(+4.4 pct) (+8.8 pct) (-16.2 pct)
EPS Basic 105.20 yen 99.62 yen 128.42 yen
EPS Diluted 105.19 yen 99.61 yen
Ann Div 56.00 yen 58.00 yen
-Q2 Div 29.00 yen 27.00 yen
-Q4 Div 29.00 yen 29.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia